Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research
ClinicalTrials.gov Identifier:
NCT01005199
First received: October 29, 2009
Last updated: March 20, 2014
Last verified: March 2014

October 29, 2009
March 20, 2014
November 2009
June 2013   (final data collection date for primary outcome measure)
Progression-free survival [ Time Frame: at 12 weeks ] [ Designated as safety issue: No ]
Progression-free survival at 12 weeks [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01005199 on ClinicalTrials.gov Archive Site
  • Objective response [ Time Frame: during trial treatment and follow-up (max. 3 years) ] [ Designated as safety issue: No ]
  • Disease stabilization (DS) [ Time Frame: under trial treatment ] [ Designated as safety issue: No ]
  • Duration of disease stabilization [ Time Frame: Duration of DS (CR, PR or SD) will be calculated from the time that measurement criteria are met for the first time until documented tumor progression. ] [ Designated as safety issue: No ]
  • Progression-free survival (PFS) [ Time Frame: PFS will be calculated from randomization until documented tumor progression or death, whichever occurs first ] [ Designated as safety issue: No ]
  • Time to progression (TTP) [ Time Frame: TTP will be calculated from randomization until documented tumor progression or tumor-related death ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: from randomization until death ] [ Designated as safety issue: No ]
  • Adverse events at baseline and during trial treatment [ Time Frame: All AEs will be assessed according to NCI CTCAE v3.0. ] [ Designated as safety issue: Yes ]
  • Serum alpha fetoprotein (AFP) level [ Time Frame: Serum AFP levels will be measured during the therapy, if AFP is ≥ 1.5 x ULN at baseline. ] [ Designated as safety issue: No ]
  • Viral reactivation in patients with chronic hepatitis B or C virus infection [ Time Frame: Number of patients with HCV/HBV (re)-activation during trial treatment ] [ Designated as safety issue: No ]
  • Correlation between vitamin B12 and overall survival [ Time Frame: The baseline vitamin B12 value, collected at trial randomization, is correlated to overall survival when dichotomized by the cut-point of 600 ng/L. ] [ Designated as safety issue: No ]
  • Objective response [ Designated as safety issue: No ]
  • Disease stabilization [ Designated as safety issue: No ]
  • Duration of disease stabilization [ Designated as safety issue: No ]
  • Progression-free survival [ Designated as safety issue: No ]
  • Time to progression [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]
  • Adverse events at baseline and during trial treatment [ Designated as safety issue: Yes ]
  • Serum alpha fetoprotein (AFP) level [ Designated as safety issue: No ]
  • Viral reactivation in patients with chronic hepatitis B or C virus infection [ Designated as safety issue: No ]
  • Vitamin B12 effect on overall survival [ Designated as safety issue: No ]
  • Quality of life at baseline and every 2 weeks for 12 weeks during study treatment [ Designated as safety issue: No ]
  • Incremental cost effectiveness ratio [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
Sorafenib Alone or in Combination With Everolimus in Patients With Unresectable Hepatocellular Carcinoma. A Randomized Multicenter Phase II Trial.

RATIONALE: Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This randomized phase II trial is studying giving sorafenib tosylate together with everolimus to see how well it works compared with sorafenib tosylate alone in treating patients with localized, unresectable, or metastatic liver cancer.

OBJECTIVES:

  • To determine if sorafenib tosylate with versus without everolimus can stop tumor progression in patients with localized, unresectable, or metastatic hepatocellular carcinoma.
  • To evaluate changes in symptom-related and global quality of life (QL) and QL benefit over the course of trial treatment in these patients.
  • To compare the primary endpoint (i.e., progression-free survival at week 12) to the QL benefit within 12 weeks from baseline.
  • To evaluate how symptom-related and global QL indicators map on the single summary index derived from a standardized measure of health status for utility cost analysis.

OUTLINE: This is a multicenter study. Patients are stratified according to WHO performance status (0 vs 1), disease spread (extrahepatic spread vs non-extrahepatic spread), and center. Patients are randomized to 1 of 2 treatment arms.

  • Arm A (standard treatment): Patients receive oral sorafenib tosylate twice daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
  • Arm B (investigational treatment): Patients receive oral sorafenib tosylate twice daily and oral everolimus once daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Some patients may undergo CT scan or MRI at baseline and at 6 and 12 weeks during study to assess tumor response, tumor size, and tumor density.

Patients complete quality of life questionnaires at baseline and every 2 weeks for 12 weeks during study treatment.

After completion of study treatment, patients are followed every 2 months for 3 years.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Liver Cancer
  • Drug: everolimus
    Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily
    Other Name: RAD001
  • Drug: sorafenib tosylate
    Sorafenib 2 x 400 mg daily
    Other Name: BAY 43-9006
  • Experimental: Arm A: Sorafenib standard
    • Arm A (standard treatment): Sorafenib 2 x 400 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (46 patients).
    Intervention: Drug: sorafenib tosylate
  • Experimental: Arm B: Sorafenib + everolimus
    • Arm B (investigational treatment): Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (60 patients)
    Interventions:
    • Drug: everolimus
    • Drug: sorafenib tosylate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
106
June 2017
June 2013   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically, cytologically, or radiologically confirmed hepatocellular carcinoma (HCC)

    • Localized, unresectable, or metastatic disease
    • Child-Pugh class A or mildly decompensated Child-Pugh class B liver dysfunction (Child-Pugh score ≤ 7)
    • Stage B or C disease according to the Barcelona Clinic Liver Cancer (BCLC) staging classification
  • Measurable disease

    • At least 1 unidimensionally measurable site of disease (≥ 10 mm in case of a non-nodal lesion or with a short axis ≥ 15 mm in case of a lymph node) by spiral/multi-slice CT/MRI scan according to revised RECIST criteria
  • No locally advanced disease AND a candidate for radical surgery
  • No known fibrolamellar HCC or mixed cholangiocarcinoma/HCC
  • No clinical symptoms or history of CNS metastases or leptomeningeal disease (no imaging required)

PATIENT CHARACTERISTICS:

  • WHO performance status 0-1
  • Hemoglobin ≥ 90 g/L
  • Neutrophil count ≥ 1.5 x 10^9/L
  • Platelet count ≥ 75 x 10^9/L
  • Creatinine clearance ≥ 40 mL/min
  • ALT ≤ 5 times upper limit of normal
  • INR ≤ 2
  • Urine dipstick for proteinuria ≤ 1+ OR protein spot urine < 0.6 g/L
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 12 months after completion of study therapy
  • No prior malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or localized nonmelanoma skin cancer
  • No history of hemorrhagic or thrombotic cerebrovascular event within the past 12 months
  • No documented variceal hemorrhage within the past 3 months
  • No requirement for anticoagulant therapy except for low-dose anticoagulants for maintenance of patency of central venous access or prevention of deep vein thrombosis
  • No history or presence of clinically significant acute or unstable cardiovascular, cerebrovascular, renal, gastrointestinal, pulmonary, endocrine, central nervous system, or immunological disorders (except for the presence of hepatitis B or C virus or cirrhosis) within the past 6 months
  • No encephalopathy
  • No known HIV infection
  • No active infection requiring IV antibiotics
  • No arterial hypertension ≥ 150/100 mm Hg despite therapy
  • No ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2, atrial fibrillation of any grade, prolongation of QTc > 500 msec on screening electrocardiogram (ECG), or history of familial long QT syndrome
  • No repeated paracentesis (more than 1 per month)
  • No psychiatric disorder precluding understanding of information of trial-related topics, giving informed consent, or interfering with compliance for oral drug intake
  • No concurrent grapefruit, grapefruit juice, or products containing bitter oranges
  • Able to take oral medications
  • Completed baseline quality of life questionnaire
  • Must be compliant and geographically proximal for follow-up

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior systemic anticancer treatment for this disease

    • The following prior therapies are allowed provided previously treated lesions remain separate from those to be measured in the current trial and prior treatment is completed within the past 4 weeks

      • Surgery
      • Liver-directed therapy (e.g., transarterial embolization/chemoembolization [limited to 5 treatments], radiofrequency ablation, cryoablation, radiotherapy, or percutaneous ethanol injection)
  • No prior organ transplantation
  • No concurrent estrogen-containing supplementary therapy
  • No concurrent full-dose anticoagulation with coumarin derivatives
  • No concurrent elective major surgery
  • No concurrent radiotherapy (concurrent analgesic radiotherapy of non-target lesions allowed)
  • No concurrent or anticipated need for CYP3A4 inhibitors or inducers, unless the drugs are medically necessary and no substitutes are available, including any of the following:

    • Ketoconazole
    • Itraconazole
    • Voriconazole
    • Erythromycin
    • Clarithromycin
    • Diltiazem
    • Verapamil
    • Protease inhibitors
  • No concurrent strong CYP3A4 inducers*, including any of the following:

    • Carbamazepine
    • Continuous dexamethasone (> 2 mg/day for > 7 days)
    • Phenobarbital
    • Phenytoin
    • Rifampicin
    • St. John's wort NOTE: *Concurrent antacids allowed provided they are administered > 1 hour before or > 1 hour after trial drug administration.
  • No other concurrent experimental drugs or anticancer therapy or treatment in another clinical trial within the past 30 days
  • No other concurrent investigational drugs
  • No chronic systemic steroids or other immunosuppressive agents
  • No concurrent angiotension converting enzyme inhibitors (ACE-I)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Hungary,   Switzerland
 
NCT01005199
SAKK 77/08 and SASL 29, SWS-SAKK-77/08, SWS-SASL-29, EUDRACT-2009-011884-35, EU-20983, CDR0000657702
No
Swiss Group for Clinical Cancer Research
Swiss Group for Clinical Cancer Research
Not Provided
Study Chair: Dieter Koeberle, MD Cantonal Hospital of St. Gallen
Study Chair: Jean-Francois Dufour, MD University Hospital Inselspital, Berne
Study Chair: Gyorgy Bodoky, MD, PhD Szent Laszlo Korhaz
Study Chair: Michael Montemurro, MD CHUV Lausanne
Swiss Group for Clinical Cancer Research
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP